Departments of Medical Biophysics and Radiation Oncology,
University of Toronto,
Ontario Cancer Institute,
Departments of Medical Biophysics and Radiation Oncology, University of Toronto, Ontario Cancer Institute
Andrew M. Rauth has not added Biography.
If you are Andrew M. Rauth and would like to personalize this page please email our Author Liaison for assistance.
Delivery of an anticancer drug and a chemosensitizer to murine breast sarcoma by intratumoral injection of sulfopropyl dextran microspheres.
The Journal of pharmacy and pharmacology Aug, 2003 | Pubmed ID: 12956895
A new approach to the in vivo and in vitro investigation of drug release from locoregionally delivered microspheres.
Journal of controlled release : official journal of the Controlled Release Society Nov, 2004 | Pubmed ID: 15491816
In vivo efficacy and toxicity of intratumorally delivered mitomycin C and its combination with doxorubicin using microsphere formulations.
Anti-cancer drugs Apr, 2005 | Pubmed ID: 15746579
Prediction of kinetics of doxorubicin release from sulfopropyl dextran ion-exchange microspheres using artificial neural networks.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences Apr, 2005 | Pubmed ID: 15784330
Biodegradable dextran-based microspheres for delivery of anticancer drug mitomycin C.
Biomaterials Sep, 2005 | Pubmed ID: 15814136
In vitro toxicity to breast cancer cells of microsphere-delivered mitomycin C and its combination with doxorubicin.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V Apr, 2006 | Pubmed ID: 16330194
A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system.
The Journal of pharmacology and experimental therapeutics Jun, 2006 | Pubmed ID: 16547167
A new polymer-lipid hybrid nanoparticle system increases cytotoxicity of doxorubicin against multidrug-resistant human breast cancer cells.
Pharmaceutical research Jul, 2006 | Pubmed ID: 16786442
Screening of lipid carriers and characterization of drug-polymer-lipid interactions for the rational design of polymer-lipid hybrid nanoparticles (PLN).
Pharmaceutical research Aug, 2006 | Pubmed ID: 16850265
Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles.
Advanced drug delivery reviews Jul, 2007 | Pubmed ID: 17532091
Molecular interactions, internal structure and drug release kinetics of rationally developed polymer-lipid hybrid nanoparticles.
Journal of controlled release : official journal of the Controlled Release Society May, 2008 | Pubmed ID: 18406489
On the synergistic effect of doxorubicin and mitomycin C against breast cancer cells.
Drug metabolism and drug interactions , 2007 | Pubmed ID: 18447000
A novel doxorubicin-mitomycin C co-encapsulated nanoparticle formulation exhibits anti-cancer synergy in multidrug resistant human breast cancer cells.
Breast cancer research and treatment Jan, 2010 | Pubmed ID: 19221875
Thermally-triggered 'off-on-off' response of gadolinium-hydrogel-lipid hybrid nanoparticles defines a customizable temperature window for non-invasive magnetic resonance imaging thermometry.
Journal of controlled release : official journal of the Controlled Release Society Feb, 2012 | Pubmed ID: 21939700
Doxorubicin and mitomycin C co-loaded polymer-lipid hybrid nanoparticles inhibit growth of sensitive and multidrug resistant human mammary tumor xenografts.
Cancer letters Jul, 2013 | Pubmed ID: 22902994
A novel solid lipid nanoparticle formulation for active targeting to tumor α(v) β(3) integrin receptors reveals cyclic RGD as a double-edged sword.
Advanced healthcare materials Sep, 2012 | Pubmed ID: 23184795
Multifunctional terpolymeric MRI contrast agent with superior signal enhancement in blood and tumor.
Journal of controlled release : official journal of the Controlled Release Society Apr, 2013 | Pubmed ID: 23353806
Matrigel alters the pathophysiology of orthotopic human breast adenocarcinoma xenografts with implications for nanomedicine evaluation.
Nanomedicine : nanotechnology, biology, and medicine Aug, 2013 | Pubmed ID: 23434679
Synergistic nanoparticulate drug combination overcomes multidrug resistance, increases efficacy, and reduces cardiotoxicity in a nonimmunocompromised breast tumor model.
Molecular pharmaceutics Aug, 2014 | Pubmed ID: 24830351
A novel nanoparticle formulation overcomes multiple types of membrane efflux pumps in human breast cancer cells.
Drug delivery and translational research Apr, 2012 | Pubmed ID: 25786718
Evaluation of new bi-functional terpolymeric nanoparticles for simultaneous in vivo optical imaging and chemotherapy of breast cancer.
Drug delivery and translational research Dec, 2012 | Pubmed ID: 25787324
Optimizing the design and in vitro evaluation of bioreactive glucose oxidase-microspheres for enhanced cytotoxicity against multidrug resistant breast cancer cells.
Colloids and surfaces. B, Biointerfaces Jun, 2015 | Pubmed ID: 25896537
Manganese oxide and docetaxel co-loaded fluorescent polymer nanoparticles for dual modal imaging and chemotherapy of breast cancer.
Journal of controlled release : official journal of the Controlled Release Society Jul, 2015 | Pubmed ID: 25908171
Optimization of controlled release nanoparticle formulation of verapamil hydrochloride using artificial neural networks with genetic algorithm and response surface methodology.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V Aug, 2015 | Pubmed ID: 25986587
Polymer-lipid hybrid nanoparticles synchronize pharmacokinetics of co-encapsulated doxorubicin-mitomycin C and enable their spatiotemporal co-delivery and local bioavailability in breast tumor.
Nanomedicine : nanotechnology, biology, and medicine Jul, 2016 | Pubmed ID: 26772427
Hybrid Manganese Dioxide Nanoparticles Potentiate Radiation Therapy by Modulating Tumor Hypoxia.
Cancer research Nov, 2016 | Pubmed ID: 27758881
JoVE 소개
Copyright © 2024 MyJoVE Corporation. 판권 소유